Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19207816 | STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE | May 2025 | September 2025 | Allow | 5 | 2 | 0 | No | No |
| 19208416 | METHODS OF TREATMENT WITH ELINZANETANT | May 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 18942141 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | November 2024 | September 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18932827 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | October 2024 | May 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18908278 | Oral Allopregnanolone Compositions and Methods of Use | October 2024 | May 2025 | Allow | 7 | 1 | 0 | No | No |
| 18660698 | ANTICANCER COMPOSITIONS | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18636148 | METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18606788 | Method and Composition for Treating Non-Cirrhotic Nash | March 2024 | January 2026 | Allow | 22 | 4 | 1 | No | Yes |
| 18581880 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | February 2024 | February 2026 | Allow | 24 | 1 | 0 | No | No |
| 18444104 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | February 2024 | June 2024 | Allow | 4 | 1 | 0 | No | No |
| 18419636 | ORAL SOLUTION FORMULATION | January 2024 | September 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18420659 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18411576 | PSILOCIN MUCATE | January 2024 | August 2024 | Allow | 7 | 1 | 1 | No | No |
| 18402989 | ETHYL 3-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]PROPANOATE AS AN ANTIMICROBIAL COMPOUND | January 2024 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18545880 | LEVOTHYROXINE LIQUID FORMULATIONS | December 2023 | January 2026 | Allow | 25 | 2 | 0 | No | No |
| 18518289 | METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS | November 2023 | March 2026 | Allow | 27 | 1 | 0 | No | No |
| 18505726 | DUAL ACTIVE INSECTICIDAL COMPOSITIONS | November 2023 | January 2026 | Allow | 27 | 3 | 0 | Yes | No |
| 18385648 | 8-(3-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18384091 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | October 2023 | August 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18494554 | Dosing Regimens for Elagolix | October 2023 | May 2025 | Allow | 19 | 1 | 0 | No | No |
| 18491503 | PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS | October 2023 | August 2025 | Allow | 22 | 1 | 0 | No | No |
| 18489863 | USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION | October 2023 | July 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18287011 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18484249 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | October 2023 | November 2025 | Abandon | 25 | 4 | 0 | No | No |
| 18377510 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS | October 2023 | March 2026 | Allow | 29 | 5 | 1 | Yes | Yes |
| 18482456 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | October 2023 | February 2025 | Abandon | 16 | 3 | 0 | No | No |
| 18481539 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18474990 | Colonic Microbiota Responsive Polymer And Its Preparation Method And Use | September 2023 | September 2024 | Allow | 11 | 0 | 0 | No | No |
| 18552297 | PYRAZOLOPYRIMIDINONE COMPOUNDS | September 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18467705 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2023 | May 2024 | Abandon | 8 | 1 | 0 | No | No |
| 18462054 | Methods of Administering Elagolix | September 2023 | March 2024 | Allow | 6 | 1 | 0 | No | No |
| 18458390 | GEL CONTAINING PIRFENIDONE | August 2023 | February 2026 | Allow | 30 | 2 | 0 | No | No |
| 18234232 | METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASE | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18219507 | THE THERAPEUTIC REGIMEN | July 2023 | December 2025 | Allow | 30 | 1 | 1 | No | No |
| 18347393 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | July 2023 | December 2024 | Abandon | 18 | 3 | 0 | No | No |
| 18216937 | LOPINAVIR AND RITONAVIR FOR THE TREATMENT OF CERVIX DISORDERS | June 2023 | March 2026 | Allow | 32 | 2 | 1 | No | No |
| 18341077 | TARGETING OCULAR DISEASES WITH NOVEL APE1/REF-1 INHIBITORS | June 2023 | November 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18340067 | STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE | June 2023 | February 2025 | Allow | 20 | 4 | 1 | No | No |
| 18336476 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18335565 | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment | June 2023 | October 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18267003 | THE USE OF THE ACTIVE COMPOUND IN THE PREVENTION OR TREATMENT OF OVARIAN DYSFUNCTION DISEASES | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18205634 | METHODS FOR TREATING GI TRACT DISORDERS | June 2023 | June 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18200152 | PROGESTOGEN-ONLY ORAL CONTRACEPTION | May 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18318210 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18317718 | Methods of Treating Heavy Menstrual Bleeding | May 2023 | November 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18316553 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18315706 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18313184 | Methods of Administering Elagolix | May 2023 | September 2025 | Allow | 28 | 1 | 1 | No | No |
| 18311334 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | May 2023 | February 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18310755 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18307048 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | April 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18296851 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | April 2023 | March 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18129177 | METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18194257 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | March 2023 | March 2024 | Abandon | 11 | 2 | 0 | No | No |
| 18192244 | ANTICANCER COMPOSITIONS | March 2023 | March 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18029362 | APPLICATION OF ALPHA-ASARONE IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING HEMORRHAGIC STROKE | March 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18028417 | FORMULATION FOR ORAL ADMINISTRATION | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18026623 | SOLID STATE FORMS OF SEP-363856 AND PROCESS FOR PREPARATION THEREOF | March 2023 | August 2025 | Allow | 29 | 0 | 0 | No | No |
| 18182797 | PEDIATRIC SUSPENSION FORMULATION | March 2023 | July 2025 | Allow | 28 | 1 | 0 | No | No |
| 18245129 | COMPOSITIONS FOR THE TREATMENT OF FAT RELATED CONDITIONS AND DISORDERS | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18044805 | METHODS OF TREATING PDE IV-MEDIATED DISEASES OR CONDITIONS | March 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18044024 | HDAC INHIBITORS FOR IDIOPATHIC PULMONARY FIBROSIS AND OTHER LUNG INFLAMMATORY DISORDERS | March 2023 | February 2026 | Allow | 35 | 2 | 0 | No | No |
| 18177585 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | March 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18171790 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | February 2023 | May 2024 | Abandon | 15 | 2 | 0 | Yes | No |
| 18022194 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18171077 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | February 2023 | December 2023 | Allow | 10 | 1 | 1 | No | No |
| 18020898 | INJECTABLE ARIPIPRAZOLE FORMULATION | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18106118 | Mucoadhesive Gel Composition | February 2023 | December 2025 | Allow | 34 | 2 | 1 | No | No |
| 18164913 | METHODS AND NUTRACEUTICAL COMPOSITIONS FOR THE PREVENTION AND/OR MITIGATION OF VEISALGIA | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18158859 | PHYTOECDYSONES FOR USE IN THE PREVENTION OF MUSCLE STRENGTH LOSS DURING IMMOBILISATION | January 2023 | November 2025 | Abandon | 34 | 2 | 0 | No | No |
| 18005035 | METHOD FOR ACTIVATING FOLLICLES BY MEANS OF USING SMALL-MOLECULE COMPOUND, AND PREPARATION THEREOF | January 2023 | December 2025 | Allow | 35 | 0 | 1 | No | No |
| 18093846 | TREATMENT OF MENSTRUAL CYCLE-INDUCED SYMPTOMS | January 2023 | September 2025 | Allow | 33 | 2 | 0 | No | No |
| 18092688 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | January 2023 | July 2023 | Allow | 6 | 1 | 0 | No | No |
| 18091510 | COMPOSITIONS THAT PREFERENTIALLY POTENTIATE SUBTYPES OF GABAA RECEPTORS AND METHODS OF USE THEREOF | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18086994 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18002169 | OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18079564 | Composition and Method for Treating Metabolic Disorders | December 2022 | October 2025 | Allow | 34 | 1 | 1 | No | No |
| 18077279 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | December 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18062764 | Method of Adjuvant Cancer Treatment | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18008505 | METHODS OF TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18059924 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | November 2022 | January 2024 | Allow | 14 | 1 | 0 | No | No |
| 18059554 | SPIRO-OXAZOLONES | November 2022 | July 2024 | Allow | 19 | 0 | 0 | No | No |
| 18053478 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | November 2022 | October 2023 | Allow | 11 | 0 | 0 | No | No |
| 17998076 | ADENOMYOSIS ASSOCIATED INFERTILITY AND HDAC INHIBITORS | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 18053248 | COMPOSITIONS FOR IMPROVING SEXUAL FUNCTION | November 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17922771 | OMEGA FATTY ACIDS-RICH OIL DISPERSION FORMULATIONS | November 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17972403 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | October 2022 | July 2025 | Allow | 32 | 2 | 0 | No | No |
| 17996770 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR COELIAC DISEASE | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17963712 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | October 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17937934 | Oral Allopregnanolone Compositions and Methods of Use | October 2022 | November 2024 | Allow | 26 | 4 | 1 | No | No |
| 17957073 | Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | September 2022 | July 2025 | Allow | 33 | 1 | 0 | No | No |
| 17952238 | Dry Powder Foamable Formulations for Delivery of Medicaments through the Mucosa | September 2022 | June 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17934889 | BORTEZOMIB COMPOSITIONS | September 2022 | April 2023 | Allow | 6 | 1 | 0 | No | No |
| 17950785 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | September 2022 | August 2024 | Allow | 23 | 0 | 1 | No | No |
| 17912942 | USE OF CYCLO-HISPRO (CHP) FOR LOWERING BLOOD PRESSURE | September 2022 | March 2026 | Allow | 42 | 2 | 0 | No | No |
| 17945865 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | September 2022 | March 2025 | Abandon | 30 | 3 | 1 | No | No |
| 17901078 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | September 2022 | June 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17823559 | TARGETING PAPAIN-LIKE PROTEASE FOR BROAD-SPECTRUM CORONAVIRUSES INHIBITION | August 2022 | January 2024 | Allow | 16 | 2 | 0 | No | No |
| 17823080 | Oral Allopregnanolone Compositions and Methods of Use | August 2022 | March 2024 | Allow | 18 | 2 | 1 | No | No |
| 17893999 | COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS | August 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUI, SAN MING R.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUI, SAN MING R works in Art Unit 1627 and has examined 366 patent applications in our dataset. With an allowance rate of 66.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner HUI, SAN MING R's allowance rate of 66.7% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HUI, SAN MING R receive 1.85 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUI, SAN MING R is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +22.9% benefit to allowance rate for applications examined by HUI, SAN MING R. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.6% of applications are subsequently allowed. This success rate is in the 61% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 47.3% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.9% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 35.6% are granted (fully or in part). This grant rate is in the 23% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.4% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.